Lake Street raised the firm’s price target on ClearPoint Neuro (CLPT) to $17 from $15 and keeps a Buy rating on the shares. Q3 outperformance was driven by another quarter of broad-business strength, says the firm, which tells investors that “the business has significant growth momentum, expectations are in check, profitability is improving, and the balance sheet is solid.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio